Spire Wealth Management Sells 7,190 Shares of Novo Nordisk A/S (NYSE:NVO)

Spire Wealth Management lowered its holdings in shares of Novo Nordisk A/S (NYSE:NVO) by 37.7% during the 4th quarter, Holdings Channel.com reports. The firm owned 11,884 shares of the company’s stock after selling 7,190 shares during the quarter. Spire Wealth Management’s holdings in Novo Nordisk A/S were worth $1,022,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently made changes to their positions in NVO. Daiwa Securities Group Inc. bought a new position in shares of Novo Nordisk A/S during the 3rd quarter valued at $28,000. Capital Performance Advisors LLP bought a new stake in Novo Nordisk A/S in the 3rd quarter worth $42,000. Albion Financial Group UT grew its holdings in Novo Nordisk A/S by 121.4% in the 4th quarter. Albion Financial Group UT now owns 507 shares of the company’s stock worth $44,000 after acquiring an additional 278 shares during the last quarter. Sound Income Strategies LLC grew its holdings in Novo Nordisk A/S by 82.1% in the 4th quarter. Sound Income Strategies LLC now owns 539 shares of the company’s stock worth $46,000 after acquiring an additional 243 shares during the last quarter. Finally, Carolina Wealth Advisors LLC bought a new stake in Novo Nordisk A/S in the 3rd quarter worth $48,000. Institutional investors own 11.54% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on the stock. Cantor Fitzgerald reissued an “overweight” rating and issued a $160.00 price target on shares of Novo Nordisk A/S in a report on Wednesday, November 6th. UBS Group raised shares of Novo Nordisk A/S from a “sell” rating to a “buy” rating in a research report on Wednesday, January 8th. StockNews.com cut shares of Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research report on Sunday, December 29th. BNP Paribas raised shares of Novo Nordisk A/S to a “strong-buy” rating in a research report on Monday, December 2nd. Finally, BMO Capital Markets dropped their target price on shares of Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating for the company in a research report on Monday, December 23rd. One investment analyst has rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Buy” and a consensus target price of $145.25.

Novo Nordisk A/S Trading Down 0.1 %

Shares of NYSE NVO opened at $82.60 on Wednesday. Novo Nordisk A/S has a 1 year low of $78.17 and a 1 year high of $148.15. The stock has a market cap of $370.65 billion, a P/E ratio of 26.73, a price-to-earnings-growth ratio of 0.93 and a beta of 0.45. The firm has a 50-day moving average of $93.12 and a 200 day moving average of $112.54. The company has a debt-to-equity ratio of 0.43, a current ratio of 0.94 and a quick ratio of 0.75.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.